Friday, August 12, 2022
No menu items!

Amryt Pharma reports record quarterly sales.

Must Read

Amryt Pharma announces record-breaking revenue for the most recent quarter.

Amryt Pharma said today that it had begun a share buyback program and recorded record sales for the second quarter ending June 30th.

According to the company’s financials, sales for the first half of the year were 9.2% higher than the same time in the previous year, bringing total revenue to $68.5 million.

Prior to financing charges, Amryt’s second-quarter operational loss was $6.9 million, compared to a $4.1 million operating loss in the same period of the preceding year.

Chiasma restructuring and acquisition costs were excluded from the $13.3 million in EBITDA, which resulted in an EBITDA before restructuring and acquisition costs of $13.3 million.

E.C. approval of Filsuvez for EB patients six months or older was granted by the European Commission during this quarter.

An Amryt spokesman said this clearance was a key milestone in the company’s history and a substantial boost for European patients with the debilitating ailment.

By excluding the impact of a single LATAM order placed in the second quarter of 2013, Methyleptin’s sales climbed 49.9 percent year over year in the second quarter.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News

Scarlet and Violet Might Reintroduce a Contentious Pokemon Feature.

The disputed Sword and Shield feature will reportedly return in Pokemon Scarlet and Violet, according to rumors. Even among those...

More Articles Like This